Contract Development and Manufacturing Organization further expands its commitment to climate protection

• Focus on energy-efficient and environmentally friendly technology
• All European sites utilize green electricity
• Savings of more than 4,500 tons of carbon dioxide since 2014

RAVENSBURG, Germany–(BUSINESS WIRE)–Environmentally focused movements such as Fridays for Future are dedicated to increasing public awareness of climate protection. Vetter, a globally leading contract development and manufacturing organization (CDMO), is equally committed to protecting the environment and has been focused on the issue of climate change as part of its corporate agenda for many years.

In 2020, the pharmaceutical service provider reached another milestone when all its European company sites became carbon dioxide neutral. The goal was made possible thanks to a long-term sustainability strategy involving appropriate action packages. Vetter has continuously invested in energy efficient and environmentally friendly technology such as its own cogeneration units as well as solar panels and geothermal energy resulting in savings of over 4,500 tons of carbon dioxide. Since 2014, all European sites have been operating using green power from hydroelectric plants.

Any inevitable residual emissions are offset as Vetter supports climate protection projects through the purchase of carbon credits.

“As a sustainable, family-owned company we have taken our responsibility towards the environment and the issue of climate protection seriously for many years and take concrete actions to support this cause. Wherever feasible, we implement the most environmentally friendly solutions,” said Managing Director Thomas Otto. The pharmaceutical industry by its very nature involves high standards and numerous regulatory requirements which are necessary to create aseptic manufacturing conditions. Vetter’s Senior Vice President for Technical Service/Internal Project Management, Henryk Badack, describes the company approach. “It is these very conditions which ultimately enable us to manufacture effective drugs for patients worldwide. However, these same high standards also make it impossible to entirely avoid residual emissions. (Read more…) That is why it is of even greater importance that we compensate for them in a sensible way.” Carbon dioxide compensation is one approach, i.e., the emissions of greenhouse gases are offset by financing climate protection activities.

“We will continue to work on keeping our company’s ecological footprint as small as possible,” said Managing Director Peter Soelkner. “As a company with a long-term focus, we consider this an important part of our social responsibility efforts not just for today, but for generations to come.” In addition to reducing greenhouse gases, the company is also focusing on environmentally friendly cooperation. For example, Vetter integrates its suppliers in ecological matters in order to promote the use of energy-efficient technologies. Beyond its core business, the pharmaceutical service provider makes an important contribution to improving the quality of life through these sustainability activities.

Please find an interview on the subject of responsibility with Managing Director Peter Soelkner here.

Find the Vetter press kit and more background information here.

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. Currently employing 5,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Contacts

Vetter Pharma International GmbH

Markus Kirchner

Corporate Spokesperson / Media Relations

Phone: +49 (0)751-3700-3729

E-mail: [email protected]

Contract Development and Manufacturing Organization further expands its commitment to climate protection

• Focus on energy-efficient and environmentally friendly technology
• All European sites utilize green electricity
• Savings of more than 4,500 tons of carbon dioxide since 2014

RAVENSBURG, Germany–(BUSINESS WIRE)–Environmentally focused movements such as Fridays for Future are dedicated to increasing public awareness of climate protection. Vetter, a globally leading contract development and manufacturing organization (CDMO), is equally committed to protecting the environment and has been focused on the issue of climate change as part of its corporate agenda for many years.

In 2020, the pharmaceutical service provider reached another milestone when all its European company sites became carbon dioxide neutral. The goal was made possible thanks to a long-term sustainability strategy involving appropriate action packages. Vetter has continuously invested in energy efficient and environmentally friendly technology such as its own cogeneration units as well as solar panels and geothermal energy resulting in savings of over 4,500 tons of carbon dioxide. Since 2014, all European sites have been operating using green power from hydroelectric plants.

Any inevitable residual emissions are offset as Vetter supports climate protection projects through the purchase of carbon credits.

“As a sustainable, family-owned company we have taken our responsibility towards the environment and the issue of climate protection seriously for many years and take concrete actions to support this cause. Wherever feasible, we implement the most environmentally friendly solutions,” said Managing Director Thomas Otto. The pharmaceutical industry by its very nature involves high standards and numerous regulatory requirements which are necessary to create aseptic manufacturing conditions. Vetter’s Senior Vice President for Technical Service/Internal Project Management, Henryk Badack, describes the company approach. “It is these very conditions which ultimately enable us to manufacture effective drugs for patients worldwide. However, these same high standards also make it impossible to entirely avoid residual emissions. (Read more…) That is why it is of even greater importance that we compensate for them in a sensible way.” Carbon dioxide compensation is one approach, i.e., the emissions of greenhouse gases are offset by financing climate protection activities.

“We will continue to work on keeping our company’s ecological footprint as small as possible,” said Managing Director Peter Soelkner. “As a company with a long-term focus, we consider this an important part of our social responsibility efforts not just for today, but for generations to come.” In addition to reducing greenhouse gases, the company is also focusing on environmentally friendly cooperation. For example, Vetter integrates its suppliers in ecological matters in order to promote the use of energy-efficient technologies. Beyond its core business, the pharmaceutical service provider makes an important contribution to improving the quality of life through these sustainability activities.

Please find an interview on the subject of responsibility with Managing Director Peter Soelkner here.

Find the Vetter press kit and more background information here.

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. Currently employing 5,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Contacts

Vetter Pharma International GmbH

Markus Kirchner

Corporate Spokesperson / Media Relations

Phone: +49 (0)751-3700-3729

E-mail: [email protected]

Contract Development and Manufacturing Organization further expands its commitment to climate protection

• Focus on energy-efficient and environmentally friendly technology
• All European sites utilize green electricity
• Savings of more than 4,500 tons of carbon dioxide since 2014

RAVENSBURG, Germany–(BUSINESS WIRE)–Environmentally focused movements such as Fridays for Future are dedicated to increasing public awareness of climate protection. Vetter, a globally leading contract development and manufacturing organization (CDMO), is equally committed to protecting the environment and has been focused on the issue of climate change as part of its corporate agenda for many years.

In 2020, the pharmaceutical service provider reached another milestone when all its European company sites became carbon dioxide neutral. The goal was made possible thanks to a long-term sustainability strategy involving appropriate action packages. Vetter has continuously invested in energy efficient and environmentally friendly technology such as its own cogeneration units as well as solar panels and geothermal energy resulting in savings of over 4,500 tons of carbon dioxide. Since 2014, all European sites have been operating using green power from hydroelectric plants.

Any inevitable residual emissions are offset as Vetter supports climate protection projects through the purchase of carbon credits.

“As a sustainable, family-owned company we have taken our responsibility towards the environment and the issue of climate protection seriously for many years and take concrete actions to support this cause. Wherever feasible, we implement the most environmentally friendly solutions,” said Managing Director Thomas Otto. The pharmaceutical industry by its very nature involves high standards and numerous regulatory requirements which are necessary to create aseptic manufacturing conditions. Vetter’s Senior Vice President for Technical Service/Internal Project Management, Henryk Badack, describes the company approach. “It is these very conditions which ultimately enable us to manufacture effective drugs for patients worldwide. However, these same high standards also make it impossible to entirely avoid residual emissions. (Read more…) That is why it is of even greater importance that we compensate for them in a sensible way.” Carbon dioxide compensation is one approach, i.e., the emissions of greenhouse gases are offset by financing climate protection activities.

“We will continue to work on keeping our company’s ecological footprint as small as possible,” said Managing Director Peter Soelkner. “As a company with a long-term focus, we consider this an important part of our social responsibility efforts not just for today, but for generations to come.” In addition to reducing greenhouse gases, the company is also focusing on environmentally friendly cooperation. For example, Vetter integrates its suppliers in ecological matters in order to promote the use of energy-efficient technologies. Beyond its core business, the pharmaceutical service provider makes an important contribution to improving the quality of life through these sustainability activities.

Please find an interview on the subject of responsibility with Managing Director Peter Soelkner here.

Find the Vetter press kit and more background information here.

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. Currently employing 5,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Contacts

Vetter Pharma International GmbH

Markus Kirchner

Corporate Spokesperson / Media Relations

Phone: +49 (0)751-3700-3729

E-mail: [email protected]